Research programme: neuroprotectant - Zocere/University of New Mexico
Latest Information Update: 16 Jul 2015
At a glance
- Originator University of New Mexico
- Developer Zocere
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Stroke